<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030004198A1-20030102-C00001.CDX SYSTEM "US20030004198A1-20030102-C00001.CDX" NDATA CDX>
<!ENTITY US20030004198A1-20030102-C00001.MOL SYSTEM "US20030004198A1-20030102-C00001.MOL" NDATA MOL>
<!ENTITY US20030004198A1-20030102-C00001.TIF SYSTEM "US20030004198A1-20030102-C00001.TIF" NDATA TIF>
<!ENTITY US20030004198A1-20030102-C00002.CDX SYSTEM "US20030004198A1-20030102-C00002.CDX" NDATA CDX>
<!ENTITY US20030004198A1-20030102-C00002.MOL SYSTEM "US20030004198A1-20030102-C00002.MOL" NDATA MOL>
<!ENTITY US20030004198A1-20030102-C00002.TIF SYSTEM "US20030004198A1-20030102-C00002.TIF" NDATA TIF>
<!ENTITY US20030004198A1-20030102-C00003.CDX SYSTEM "US20030004198A1-20030102-C00003.CDX" NDATA CDX>
<!ENTITY US20030004198A1-20030102-C00003.MOL SYSTEM "US20030004198A1-20030102-C00003.MOL" NDATA MOL>
<!ENTITY US20030004198A1-20030102-C00003.TIF SYSTEM "US20030004198A1-20030102-C00003.TIF" NDATA TIF>
<!ENTITY US20030004198A1-20030102-C00004.CDX SYSTEM "US20030004198A1-20030102-C00004.CDX" NDATA CDX>
<!ENTITY US20030004198A1-20030102-C00004.MOL SYSTEM "US20030004198A1-20030102-C00004.MOL" NDATA MOL>
<!ENTITY US20030004198A1-20030102-C00004.TIF SYSTEM "US20030004198A1-20030102-C00004.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030004198</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>09995267</doc-number>
</application-number>
<application-number-series-code>09</application-number-series-code>
<filing-date>20011127</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>2001-0024988</doc-number>
</priority-application-number>
<filing-date>20010508</filing-date>
<country-code>KR</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>A61K031/425</ipc>
</classification-ipc-primary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>514</class>
<subclass>372000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>424</class>
<subclass>663000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Stabilized isothiazolone-containing compositions</title-of-invention>
</technical-information>
<inventors>
<first-named-inventor>
<name>
<given-name>Miron</given-name>
<middle-name>Gerard</middle-name>
<family-name>Still</family-name>
</name>
<residence>
<residence-us>
<city>Richmond</city>
<state>VA</state>
<country-code>US</country-code>
</residence-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Wan</given-name>
<middle-name>Pyo</middle-name>
<family-name>Hong</family-name>
</name>
<residence>
<residence-non-us>
<city>Whasung-gun</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Jin</given-name>
<middle-name>Man</middle-name>
<family-name>Kim</family-name>
</name>
<residence>
<residence-non-us>
<city>Suwon-si</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Ki</given-name>
<middle-name>Seung</middle-name>
<family-name>Choi</family-name>
</name>
<residence>
<residence-non-us>
<city>Euiwhang-si</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Jung</given-name>
<middle-name>Ho</middle-name>
<family-name>Park</family-name>
</name>
<residence>
<residence-non-us>
<city>Suwon-si</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Jae</given-name>
<middle-name>Min</middle-name>
<family-name>Ha</family-name>
</name>
<residence>
<residence-non-us>
<city>Suwon-si</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Hi</given-name>
<middle-name>Weon</middle-name>
<family-name>Jung</family-name>
</name>
<residence>
<residence-non-us>
<city>Suwon-si</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Soon</given-name>
<middle-name>Jong</middle-name>
<family-name>Hahn</family-name>
</name>
<residence>
<residence-non-us>
<city>Seoul</city>
<country-code>KR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<assignee>
<organization-name>LONZA INC.</organization-name>
<assignee-type>02</assignee-type>
</assignee>
<correspondence-address>
<name-1>DARBY &amp; DARBY P.C.</name-1>
<name-2></name-2>
<address>
<address-1>805 Third Avenue</address-1>
<city>New York</city>
<state>NY</state>
<postalcode>10022</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">The present invention relates to isothiazolone-containing compositions comprising a) 3-isothiazolone compounds; b) a metal nitrate; c) magnesium chloride; d) at least one compound selected from the group consisting of iodic acid, periodic acid, an iodate salt, and a periodate salt; e) chlorite salts; and f) solvents. The invention further provides a method for stabilizing isothiazolone-containing compositions by inhibiting precipitation of by-products formed during production and precipitation of the compounds formed during storage. The compositions of the invention are useful for suppressing the growth of microorganisms. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> This application claims priority of Korean Patent Application No. 2001-0024988, filed on May 8, 2001, the content of which is incorporated herein by reference. </paragraph>
<section>
<heading lvl="1">BACKGROUND OF THE INVENTION </heading>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> 1. Field of the Invention </paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> The present invention relates to isothiazolone-containing compositions and a method for stabilizing them. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> 2. Description of the Related Art </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> Isothiazolones are compounds having wide-ranging sterilizing activity against many harmful organisms derived from animals and plants such as bacteria, fungi, algae, etc. Isothiazolones are added to products such as cosmetics and paints to inhibit the growth of harmful microorganisms in these products. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> 3-Isothiazolones decompose readily in polar organic solvents such as alcohol or water, and lose their biological activity with the lapse of time. Typically, a metal nitrate, such as magnesium nitrate, is added to most commercially available 3-isothiazolone-containing compositions to stabilize the 3-isothiazolones; such isothiazolone-containing compositions typically contain 1 to 20% by weight of isothiazolones and 15 to 25% by weight of the metal nitrate. A method for the prevention of chemical decomposition of 3-isothiazolones by adding a metal nitrite, a metal nitrate, etc., is disclosed in U.S. Pat. No. 3,870,795. </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> Although using metal nitrates as stabilizers of 3-isothiazolones preserves their sterilizing activity for longer periods of time, traces of precipitates are formed from the decomposition of 3-isothiazolone in solution during storage. The trace amounts of precipitates do not deleteriously impact the biological efficacy of isothiazolones; however, the presence of the precipitates gives an undesirable appearance to products, which is detrimental from a commercial standpoint. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> In another method, Japanese Patent Publication No. 02-304005 discloses compositions containing 0.1 to 15% by weight of isothiazolones, 1 to 5000 ppm of copper ion, non-ion surfactant and organic solvents, but no nitrate salts. Japanese Patent Laid-open No. 05-170608 discloses that the use of bromic acid, iodic acid, periodic acid, iodates, and periodates instead of bivalent metal salts with magnesium nitrate as a stabilizer for isothiazolone-containing compositions can also prevent &ldquo;salt shock&rdquo; which often occurs when a metal nitrate is added to aqueous dispersions of polymers. </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> U.S. Pat. No. 5,910,503 discloses that a mixture of 0.5 to 35% by weight of isothiazolone compounds and 2 to 30% by weight of metal nitrate with 0.01 to 35% by weight of bromic acid, iodic acid, periodic acid, or salts thereof inhibits precipitation formed during storage and stabilizes aqueous dispersion of polymers (coagulation of latexes). However, in the method as above-mentioned, the amounts of bromic acid, iodic acid, periodic acid, or salts thereof used for preventing precipitate formation is very large. These large amounts thicken the compositions and, in addition, raise the cost of production of the compositions, making it economically unfeasible to employ these compositions commercially. </paragraph>
</section>
<section>
<heading lvl="1">SUMMARY OF THE INVENTION </heading>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> The present invention provides stabilized isothiazolone-containing compositions comprising two different stabilizers that can efficiently suppress precipitate formed by by-products in the compositions and formed upon storage of the compositions. </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> The present invention also provides a method for stabilizing isothiazolones by suppressing the generation of precipitates in isothiazolone-containing compositions. </paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> To achieve the above objects and others, the present invention provides an isothiazolone-containing composition comprising: </paragraph>
<paragraph id="P-0013" lvl="2"><number>&lsqb;0013&rsqb;</number> a) a 3-isothiazolone compound having the structure of the formula:  
<chemistry-cwu id="CHEM-US-00001">
<number>1</number>
<image id="EMI-C00001" he="68.63535" wi="152.4096" file="US20030004198A1-20030102-C00001.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00001" file="US20030004198A1-20030102-C00001.CDX"/>
<chemistry-mol-file id="CHEMMOL-00001" file="US20030004198A1-20030102-C00001.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0014" lvl="7"><number>&lsqb;0014&rsqb;</number> wherein: </paragraph>
<paragraph id="P-0015" lvl="2"><number>&lsqb;0015&rsqb;</number> R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are the same or different, and each is hydrogen, a halogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>4 </subscript></highlight>alkyl group, or an aryl group in which R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are cyclized, and </paragraph>
<paragraph id="P-0016" lvl="2"><number>&lsqb;0016&rsqb;</number> R<highlight><subscript>3 </subscript></highlight>is hydrogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkenyl group, a C<highlight><subscript>2</subscript></highlight>-CI<highlight><subscript>8 </subscript></highlight>alkynyl group, a C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>12 </subscript></highlight>cycloalkyl group having a ring of 3-8 angles, a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aralkyl group, or a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aryl group; </paragraph>
<paragraph id="P-0017" lvl="3"><number>&lsqb;0017&rsqb;</number> b) a metal nitrate; </paragraph>
<paragraph id="P-0018" lvl="3"><number>&lsqb;0018&rsqb;</number> c) magnesium chloride; </paragraph>
<paragraph id="P-0019" lvl="3"><number>&lsqb;0019&rsqb;</number> d) at least one of the iodine-containing compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt and a periodate salt; </paragraph>
<paragraph id="P-0020" lvl="3"><number>&lsqb;0020&rsqb;</number> e) a chlorite salt; and </paragraph>
<paragraph id="P-0021" lvl="3"><number>&lsqb;0021&rsqb;</number> f) a solvent. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> The present invention also provides a method for stabilizing isothiazolones comprising the steps of: </paragraph>
<paragraph id="P-0023" lvl="2"><number>&lsqb;0023&rsqb;</number> I) adding to a solvent </paragraph>
<paragraph id="P-0024" lvl="3"><number>&lsqb;0024&rsqb;</number> a) 0.1 to 20% by weight of an 3-isothiazolone compound of the formula:  
<chemistry-cwu id="CHEM-US-00002">
<number>2</number>
<image id="EMI-C00002" he="68.63535" wi="152.4096" file="US20030004198A1-20030102-C00002.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00002" file="US20030004198A1-20030102-C00002.CDX"/>
<chemistry-mol-file id="CHEMMOL-00002" file="US20030004198A1-20030102-C00002.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0025" lvl="7"><number>&lsqb;0025&rsqb;</number> wherein: </paragraph>
<paragraph id="P-0026" lvl="2"><number>&lsqb;0026&rsqb;</number> R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are the same or different, and each is hydrogen, a halogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>4 </subscript></highlight>alkyl group, or an aryl group in which R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are cyclized, and </paragraph>
<paragraph id="P-0027" lvl="2"><number>&lsqb;0027&rsqb;</number> R<highlight><subscript>3 </subscript></highlight>is hydrogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkenyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkynyl group, a C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>12 </subscript></highlight>cycloalkyl group having a ring of 3-8 angles, a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aralkyl group, or a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aryl group; </paragraph>
<paragraph id="P-0028" lvl="3"><number>&lsqb;0028&rsqb;</number> (b) 0.1 to 25% by weight of a metal nitrate; and </paragraph>
<paragraph id="P-0029" lvl="3"><number>&lsqb;0029&rsqb;</number> (c) 0.1 to 9.0% by weight of a magnesium chloride to form a solution; and </paragraph>
<paragraph id="P-0030" lvl="2"><number>&lsqb;0030&rsqb;</number> II) mixing </paragraph>
<paragraph id="P-0031" lvl="3"><number>&lsqb;0031&rsqb;</number> (d) 0.0001 to 0.01% by weight of at least one of the iodine-containing compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt; and a periodate salt with </paragraph>
<paragraph id="P-0032" lvl="3"><number>&lsqb;0032&rsqb;</number> (e) 0.0001 to 10% by weight of a chlorite salts to form a mixture; and </paragraph>
<paragraph id="P-0033" lvl="2"><number>&lsqb;0033&rsqb;</number> III) combining the mixture of II) with the solution of I). </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> The present invention further provides a method of suppressing the growth of microorganisms comprising introducing a 3-isothiazolone-containing composition as described above into the habitat of microorganisms. </paragraph>
</section>
<section>
<heading lvl="1">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS </heading>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> The mixing of the two types of compounds, i.e., the iodine-containing compounds and the chlorite salts defined above, each having different reaction mechanisms, with magnesium chloride in specified concentrations, inhibits or prevents precipitate formation in compositions containing isothiazolones. By using concentrations even lower than those previously disclosed, the precipitation of by-products generated in the production of the compositions and minute precipitates formed by the compounds generated during storage can be significantly reduced or prevented, thereby effectively stabilizing the isothiazolone. </paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> According to the present invention, preferred examples of the isothiazolone compounds of Formula 1 are 5-chloro-2-methyl-4-isothiazoline-3-one; 2-methyl-4-isothiazoline-3-one, 4,5-dichloro-2-methyl-4-isothiazoline-3-one; 5-chloro-2-n-octyl-3-isothiazolone; 4,5 -dichloro-2-n-octyl-3-isothiazolone and benzisothiazolone. Alternatively, a mixture of these compounds may be used, preferably, of 5-chloro-2-methyl-4-isothiazoline-3-one and 2-methyl-4-isothiazoline-3-one, wherein the weight ratio is preferably from 1:20 to 20:1. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> In the isothiazolone-containing compositions of the present invention, the isothiazolones of Formula I are used in an amount that is typically used in isothiazolone-containing solutions, namely, from 0.1 to 20% by weight of the isothiazolone. </paragraph>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> To reduce or inhibit the degradation of isothiazolones, the composition of the present invention comprises from 0.1 to 25% by weight of metal nitrate. Preferred metal nitrates include lithium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, and ammonium nitrate. Most preferred is magnesium nitrate. </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> Furthermore, the composition of the present invention preferably includes from 0.1 to 9% by weight of magnesium chloride to suppress the formation of the isothiazolone precipitate. Magnesium chloride in an amount of less than 0.1 wt % may not effectively inhibit precipitation; when present in an amount of more than 9 wt %, it may itself precipitate due to its limited solubility. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> The composition of the present invention further includes at least one of the iodine-containing compounds defined above in an amount of from about 0.0001 to 0.01 wt %, preferably from 0.001 to 0.005 wt %. If less than 0.0001 wt % is used, precipitation may not be effectively inhibited; an amount above 0.01 wt % is not preferred in commercial applications since it increases the cost without any attendant benefit. </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> The composition of the invention preferably includes chlorite salts to suppress precipitate formation. The amount of chlorite salts used is preferably from about 0.0001 to 10 wt %, more preferably from 0.0001 to 0.1 wt %. If less than 0.0001 wt % is used, it may not be effective in preventing precipitation; an amount above 10 wt % is not preferred in commercial applications due to the increased cost. The chlorite salts are preferably sodium chlorite, potassium chlorite, and mixtures thereof. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> The isothiazolone compounds are stabilized by using the chlorite salts together with at least one iodine-containing compound, most preferably in a weight ratio of the iodine-containing compounds to the chlorite salts of from 0.001:0.005 to 0.0001:0.05. Preferred iodine-containing compounds include lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, and ammonium periodate. Most preferred are iodic acid, periodate dihydrate, potassium iodate, and sodium iodate. </paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number> The composition of the invention further comprises at least one solvent. Preferred solvents include water, ethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, 1.5-pentanediol, 2,4-pentanediol, benzyl alcohol, and mixtures thereof. </paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> The method of the present invention for preparing isothiazolone-containing compositions comprises adding 3-isothiazolone compounds of Formula I, a metal nitrate, and a magnesium chloride to a solvent to prepare a mixed solution. Then at least one of the iodine-containing compounds is mixed with a chlorite salt. The resultant mixture is added to the solution containing 3-isothiazolone prepared in the foregoing step. </paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> The present invention further provides a method for suppressing the growth of microorganisms derived from animals and plants, for example, bacteria, fungi and algae. According to the present invention, the growth of microorganisms may be inhibited or the microorganisms may be killed. The isothiazolone-containing compositions of the invention may be introduced into the habitats of any microorganisms, including cooling towers, air washers, boilers, mineral slurries, wastewater treatments, ornamental fountains, reverse osmosis filtration systems, ultrafiltration systems, ballast water, evaporative condensers, heat exchangers, pulp and paper processing fluids, plastics, emulsions and dispersions, paints, latexes, coating agents and metal working fluids. </paragraph>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number> To better define the present invention, the following Examples are set forth. These Examples are only to better the understanding of the invention, but are not intended to limit its scope.</paragraph>
</section>
</summary-of-invention>
<detailed-description>
<section>
<heading lvl="1">EXAMPLES </heading>
</section>
<section>
<heading lvl="1">Examples 1 and 2 </heading>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> The content of the 3-isothiazolone compositions of Examples 1 and 2 are shown below in Table 1. 3-Isothiazolone compounds were prepared by using an approximate 3:1 mixture of 5-chloro-2-methyl-4-isothiazoline-3-one (CMI) and 2-methyl-4-isothiazoline-3-one (MI). The compositions of Examples 1 and 2 were prepared by mixing 3-isothiazolone compounds, magnesium nitrate, magnesium chloride, and water, followed by adding KIO<highlight><subscript>3 </subscript></highlight>(Example 1 only) and 25% NaClO<highlight><subscript>2</subscript></highlight>, HIO<highlight><subscript>4</subscript></highlight>. 2H<highlight><subscript>2</subscript></highlight>O (Example 2 only) and 25% NaClO<highlight><subscript>2</subscript></highlight>, respectively, for preventing precipitation. </paragraph>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> The isothiazolone compositions of Comparative Examples 1 to 4 having the content shown below in Table 1 were prepared as described above. Each isothiazolone-containing solution was stored in an oven at 65&deg; C. for 92 days, then analyzed by HPLC to determine the percentage of CMI remaining in the compositions. The results are shown below in Table 2.  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="35PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="21PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="8" align="center">TABLE 1</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Sam-</entry>
<entry>CMI &plus;</entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>HIO<highlight><subscript>4 </subscript></highlight>&middot;</entry>
<entry>25%</entry>
<entry></entry>
</row>
<row>
<entry>ple</entry>
<entry>MI</entry>
<entry>Mg(NO<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight></entry>
<entry>MgCl<highlight><subscript>2</subscript></highlight></entry>
<entry>KIO<highlight><subscript>3</subscript></highlight></entry>
<entry>2H<highlight><subscript>2</subscript></highlight>O</entry>
<entry>NaClO<highlight><subscript>2</subscript></highlight></entry>
<entry>Water</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="21PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="35PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="21PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<colspec colname="7" colwidth="28PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>Com-</entry>
<entry>14.7</entry>
<entry>17.4</entry>
<entry>4.1</entry>
<entry>&mdash;</entry>
<entry>&mdash;</entry>
<entry>&mdash;</entry>
<entry>63.8</entry>
</row>
<row>
<entry>para-</entry>
<entry></entry>
</row>
<row>
<entry>tive</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry></entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 1</entry>
<entry></entry>
</row>
<row>
<entry>Com-</entry>
<entry>14.7</entry>
<entry>17.4</entry>
<entry>4.1</entry>
<entry>0.005</entry>
<entry>&mdash;</entry>
<entry>&mdash;</entry>
<entry>63.79</entry>
</row>
<row>
<entry>para-</entry>
<entry></entry>
</row>
<row>
<entry>tive</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry></entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 2</entry>
<entry></entry>
</row>
<row>
<entry>Com-</entry>
<entry>14.7</entry>
<entry>17.4</entry>
<entry>4.1</entry>
<entry>&mdash;</entry>
<entry>&mdash;</entry>
<entry>0.2</entry>
<entry>63.6</entry>
</row>
<row>
<entry>para-</entry>
<entry></entry>
</row>
<row>
<entry>tive</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry></entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 3</entry>
<entry></entry>
</row>
<row>
<entry>Com-</entry>
<entry>11.7</entry>
<entry>17.4</entry>
<entry>&mdash;</entry>
<entry>0.005</entry>
<entry>&mdash;</entry>
<entry>0.2</entry>
<entry>70.69</entry>
</row>
<row>
<entry>para-</entry>
<entry></entry>
</row>
<row>
<entry>tive</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry></entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 4</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry>14.7</entry>
<entry>17.4</entry>
<entry>4.1</entry>
<entry>0.005</entry>
<entry>&mdash;</entry>
<entry>0.2</entry>
<entry>63.59</entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 1</entry>
<entry></entry>
</row>
<row>
<entry>Ex-</entry>
<entry>14.7</entry>
<entry>17.4</entry>
<entry>4.1</entry>
<entry>&mdash;</entry>
<entry>0.0005</entry>
<entry>0.2</entry>
<entry>63.59</entry>
</row>
<row>
<entry>am-</entry>
<entry></entry>
</row>
<row>
<entry>ple 2</entry>
</row>
<row><entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number>  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="42PT" align="left"/>
<colspec colname="1" colwidth="91PT" align="center"/>
<colspec colname="2" colwidth="91PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center">TABLE 2</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Initial</entry>
<entry>After 92 days, at 65&deg; C.</entry>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="10">
<colspec colname="1" colwidth="42PT" align="left"/>
<colspec colname="2" colwidth="14PT" align="center"/>
<colspec colname="3" colwidth="21PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="center"/>
<colspec colname="6" colwidth="14PT" align="center"/>
<colspec colname="7" colwidth="21PT" align="center"/>
<colspec colname="8" colwidth="28PT" align="center"/>
<colspec colname="9" colwidth="28PT" align="center"/>
<colspec colname="10" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>CMI &plus;</entry>
<entry>CMI/MI</entry>
<entry></entry>
<entry></entry>
<entry>CMI &plus;</entry>
<entry>CMI/MI</entry>
<entry></entry>
</row>
<row>
<entry>Wt %</entry>
<entry>MI</entry>
<entry>CMI</entry>
<entry>MI</entry>
<entry>ratio</entry>
<entry>MI</entry>
<entry>CMI</entry>
<entry>MI</entry>
<entry>ratio</entry>
<entry>Precipitation</entry>
</row>
<row><entry namest="1" nameend="10" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="10">
<colspec colname="1" colwidth="42PT" align="left"/>
<colspec colname="2" colwidth="14PT" align="center"/>
<colspec colname="3" colwidth="21PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="14PT" align="center"/>
<colspec colname="7" colwidth="21PT" align="char" char="."/>
<colspec colname="8" colwidth="28PT" align="char" char="."/>
<colspec colname="9" colwidth="28PT" align="char" char="."/>
<colspec colname="10" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry>Comparative</entry>
<entry>3.9</entry>
<entry>10.8</entry>
<entry>14.7</entry>
<entry>2.76</entry>
<entry>3.6</entry>
<entry>8.5</entry>
<entry>12.1</entry>
<entry>2.36</entry>
<entry>Yes</entry>
</row>
<row>
<entry>Example 1</entry>
</row>
<row>
<entry>Comparative</entry>
<entry>3.9</entry>
<entry>10.8</entry>
<entry>14.7</entry>
<entry>2.76</entry>
<entry>3.7</entry>
<entry>9.3</entry>
<entry>13.0</entry>
<entry>2.51</entry>
<entry>Yes</entry>
</row>
<row>
<entry>Example 2</entry>
</row>
<row>
<entry>Comparative</entry>
<entry>3.9</entry>
<entry>10.8</entry>
<entry>14.7</entry>
<entry>2.76</entry>
<entry>3.6</entry>
<entry>8.6</entry>
<entry>12.2</entry>
<entry>2.38</entry>
<entry>Yes</entry>
</row>
<row>
<entry>Example 3</entry>
</row>
<row>
<entry>Comparative</entry>
<entry>1.0</entry>
<entry>10.7</entry>
<entry>11.7</entry>
<entry>10.4</entry>
<entry>0.9</entry>
<entry>7.5</entry>
<entry>8.4</entry>
<entry>8.6</entry>
<entry>Yes</entry>
</row>
<row>
<entry>Example 4</entry>
</row>
<row>
<entry>Example 1</entry>
<entry>3.9</entry>
<entry>10.8</entry>
<entry>14.7</entry>
<entry>2.76</entry>
<entry>3.9</entry>
<entry>10.7</entry>
<entry>14.6</entry>
<entry>2.72</entry>
<entry>No</entry>
</row>
<row>
<entry>Example 2</entry>
<entry>3.9</entry>
<entry>10.8</entry>
<entry>14.7</entry>
<entry>2.76</entry>
<entry>3.9</entry>
<entry>10.7</entry>
<entry>14.6</entry>
<entry>2.72</entry>
<entry>No</entry>
</row>
<row><entry namest="1" nameend="10" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number> The data in Table 2 show that, for the compositions of Comparative Examples 1 to 4, after storage for 92 days at 65&deg; C., the concentration of major constituents and the ratio of CMI/MI decreased, and precipitates were formed in all solutions. In contrast, in the compositions of Examples 1 and 2, even after storage for 92 days at 65&deg; C., the concentration of major constituents barely dropped and the ratio of CMI/MI remained high. Furthermore, no precipitate was formed in either solution, indicating that isothiazolone-containing solutions were stabilized. </paragraph>
</section>
<section>
<heading lvl="1">Experimental Example </heading>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> The number of insoluble particulates existing in compositions of Comparative Examples 1 to 3 and Examples 1 and 2 was determined when the samples were prepared, and several times during sample storage at ambient temperature. The counting of insoluble particulates was conducted by using Liquidborne Particle Counter System (Model: Cl-1000, manufactured by Climet Co.) at 10.0 ml/min of flow rate, 2.0 ml of tare volume, calculating the total number of insoluble particulates more than 1 &mgr;m, per 10.0 ml of isothiazolone-containing solutions. The results are reported below in Table 3.  
<table-cwu id="TABLE-US-00003">
<number>3</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="28PT" align="center"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="42PT" align="center"/>
<colspec colname="5" colwidth="35PT" align="center"/>
<colspec colname="6" colwidth="28PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="6" align="center">TABLE 3</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Storage</entry>
<entry>Comparative</entry>
<entry>Comparative</entry>
<entry>Comparative</entry>
<entry></entry>
<entry>Ex-</entry>
</row>
<row>
<entry>days</entry>
<entry>Example 1</entry>
<entry>Example 2</entry>
<entry>Example 3</entry>
<entry>Example 1</entry>
<entry>ample 2</entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="28PT" align="char" char="."/>
<colspec colname="2" colwidth="42PT" align="char" char="."/>
<colspec colname="3" colwidth="42PT" align="char" char="."/>
<colspec colname="4" colwidth="42PT" align="char" char="."/>
<colspec colname="5" colwidth="35PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>0</entry>
<entry>952</entry>
<entry>967</entry>
<entry>985</entry>
<entry>993</entry>
<entry>997</entry>
</row>
<row>
<entry>18</entry>
<entry>98,980</entry>
<entry>13,130</entry>
<entry>18,534</entry>
<entry>1,879</entry>
<entry>1,987</entry>
</row>
<row>
<entry>22</entry>
<entry>148,372</entry>
<entry>100,471</entry>
<entry>137,932</entry>
<entry>4,982</entry>
<entry>5,207</entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> The data in Table 3 indicates that in Comparative Examples 1 to 3 the number of insoluble particulates increased rapidly during the first 18 days and continued to increase until the 22nd day, thereby generating large amounts of precipitates. In contrast, in the compositions of Examples 1 and 2, the number of insoluble particulate increased slightly over the first 18 days and remained relatively small even after 22 days. Thus, the generation of precipitates was restrained. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<heading lvl="1">What is claimed is: </heading>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. A composition, comprising: 
<claim-text>a) a 3-isothiazolone compound of the formula </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00003">
<number>3</number>
<image id="EMI-C00003" he="61.6896" wi="60.98085" file="US20030004198A1-20030102-C00003.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00003" file="US20030004198A1-20030102-C00003.CDX"/>
<chemistry-mol-file id="CHEMMOL-00003" file="US20030004198A1-20030102-C00003.MOL"/>
</chemistry-cwu>
</claim-text>
<claim-text>wherein: </claim-text>
<claim-text>R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are the same or different, each is hydrogen, a halogen a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>4 </subscript></highlight>alkyl group, or an aryl group in which R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are cyclized; and </claim-text>
<claim-text>R<highlight><subscript>3 </subscript></highlight>is hydrogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkenyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkynyl group, a C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>12 </subscript></highlight>cycloalkyl group having a ring of 3-8 angles, a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aralkyl group, or a C<highlight><subscript>10 </subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aryl group; 
<claim-text>b) a metal nitrate; </claim-text>
<claim-text>c) magnesium chloride; </claim-text>
<claim-text>d) at least one of the iodine-containing compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt, and a periodate salt; </claim-text>
<claim-text>e) a chlorite salt; and </claim-text>
<claim-text>f) a solvent. </claim-text>
</claim-text>
</claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, comprising: 
<claim-text>a) 0.1 to 20 wt % of the 3-isothiazolone compound; </claim-text>
<claim-text>b) 0.1 to 25 wt % of the metal nitrate; </claim-text>
<claim-text>c) 0.1 to 9.0 wt % of magnesium chloride; </claim-text>
<claim-text>d) 0.0001 to 0.01 wt % of at least one of the iodine-containing compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt, and a periodate salt; </claim-text>
<claim-text>e) 0.0001 to 10 wt % of the chlorite salt. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00002">claim 2</dependent-claim-reference>, comprising 0.001 to 0.005 wt % of at least one of the compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt, and a periodate salt; and 0.0001 to 0.1 wt % of the chlorite salt. </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00002">claim 2</dependent-claim-reference>, comprising 0.001 to 0.005 wt % of at least one of the compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt, and a periodate salt; and 0.0001 to 0.05 wt % of the chlorite salt. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the 3-isothiazolone compound is selected from at least one of the compounds of the group consisting of 5-chloro-2-methyl-4-isothiazoline-3-one; 2-methyl-4-isothiazoline-3-one; 4,5-dichloro-2-methyl-4-isothiazoline-3-one; 5-chloro-2-n-octyl-3-isothiazolone; 4,5-dichloro-2-n-octyl-3-isothiazolone; and benzisothiazolone. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the metal nitrate is selected from at least one of the compounds selected from the group consisting of lithium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, and ammonium nitrate. </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the iodine-containing compound d) is at least one of the compounds selected from the group consisting of lithium iodate, sodium iodate, potassium iodate, ammonium iodate, lithium periodate, sodium periodate, potassium periodate, anunonium periodate, iodic acid, periodate dihydrate, potassium iodate, and sodium iodate. </claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the chlorite salt is at least one of the compounds selected from the group consisting of sodium chlorite and potassium chlorite. </claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. The composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference>, wherein the solvent is at least one of the compounds selected from the group consisting of water, ethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, 1.5-pentanediol, 2,4-pentanediol and benzylalcohol. </claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. A method for stabilizing an isothiazolone comprising: 
<claim-text>I.) adding to solvent 
<claim-text>i) 0.1 to 20% by weight of 3-isothiazolone compounds of the formula </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00004">
<number>4</number>
<image id="EMI-C00004" he="61.6896" wi="60.98085" file="US20030004198A1-20030102-C00004.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00004" file="US20030004198A1-20030102-C00004.CDX"/>
<chemistry-mol-file id="CHEMMOL-00004" file="US20030004198A1-20030102-C00004.MOL"/>
</chemistry-cwu>
</claim-text>
<claim-text>wherein: </claim-text>
</claim-text>
<claim-text>R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are the same or different, each is hydrogen, a halogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>4 </subscript></highlight>alkyl group, or an aryl group in which R<highlight><subscript>1 </subscript></highlight>and R<highlight><subscript>2 </subscript></highlight>are cyclized; and </claim-text>
<claim-text>R<highlight><subscript>3 </subscript></highlight>is hydrogen, a C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkenyl group, a C<highlight><subscript>2</subscript></highlight>-C<highlight><subscript>18 </subscript></highlight>alkynyl group, a C<highlight><subscript>3</subscript></highlight>-C<highlight><subscript>12 </subscript></highlight>cycloalkyl group having a ring of 3-8 angles, a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aralkyl group, or a C<highlight><subscript>10</subscript></highlight>-C<highlight><subscript>24 </subscript></highlight>aryl group; 
<claim-text>(b) 0.1 to 25% by weight of a metal nitrate; and </claim-text>
<claim-text>(c) 0.1 to 9.0% by weight of magnesium chloride to form a solution; and </claim-text>
</claim-text>
<claim-text>II) mixing 
<claim-text>(d) 0.0001 to 0.01% by weight of at least one of the iodine-containing compounds selected from the group consisting of iodic acid, periodic acid, an iodate salt; and a periodate salt with </claim-text>
<claim-text>(e) 0.0001 to 10% by weight of a chlorite salts to form a mixture; and </claim-text>
</claim-text>
<claim-text>III) combining the mixture of II) with the solution of I). </claim-text>
</claim-text>
</claim>
<claim id="CLM-00011">
<claim-text><highlight><bold>11</bold></highlight>. The method for stabilizing an isothiazolone according to <dependent-claim-reference depends_on="CLM-00011">claim 10</dependent-claim-reference>, wherein the 3-isothiazolone compound is at least one of the compounds selected from the group consisting of 5-chloro-2-methyl-4-isothiazoline-3-one; 2-methyl-4-isothiazoline-3-one; 4,5,-dichloro-2-methyl-4-isothiazoline-3-one; 5-chloro-2-n-octyl-3-isothiazolone; 4,5-dichloro-2-n-octyl-3-isothiazolone; and benzisothiazolone.</claim-text>
</claim>
</subdoc-claims>
</patent-application-publication>
